Wednesday's failure of the company's Alzheimer's drug Dimebon in a closely watched phase III study. Both Medivation and Johnson & Johnson are studying their respective drugs in other stages of prostate cancer treatment that, if approved, may not directly compete with cabazitaxel. However, these studies are not as far along. Abiraterone and MDV3100 work by interfering with the way prostate cancer cells feed from testosterone produced in the body. That's different from cabazitaxel, which interferes with cancer cell division.